Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by icecubeon Aug 26, 2015 4:45pm

43 Views

Post# 24053988

RE:Gotcha again lying about the breech

Did someone say that the breach had something to do with the stock's valuation? Not that I know of.
On the other hand ...

This might have something to do with the stock's price:

icecube wrote:

"CPH's current quarter consensus estimate has decreased notably over the past 90 days from 0.13 to -0.03, a loss of -120.0%. This trails the average Pharmaceuticals industry move of 0.0% during the same time period."